0 CHECKOUT

The Pharmaceutical Market: Slovenia

  • ID: 3229956
  • April 2015
  • Region: Slovenia
  • 96 Pages
  • Espicom Business Intelligence Ltd

FEATURED COMPANIES

  • GlaxoSmithKline (GSK)
  • Krka
  • Lek (Novartis/Sandoz)
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

Overview Of The Pharmaceutical Market In Slovenia:

Slovenia's healthcare system is relatively developed and effective, particularly compared with other markets in Central and Eastern Europe. The country's health system faces short-term challenges as a result of austerity budgets which will limit public spending on healthcare and are designed to reduce the number of services covered under compulsory health insurance. Long-term threats concern the availability of public funds in a tightening economic and fiscal environment and projected rises in age-related health expenditure.

Risk/Reward Rating:

In our Q1 assessment, we have revised downward our Pharmaceuticals and Healthcare Risk/Reward Ratings (RRRs) for Central and Eastern Europe (CEE), mainly due to the attractiveness of Poland, Greece and the Czech Republic getting worse.Downward revisions to our industry rewards indicators for CEE are a result of moderated outlooks in many pharmaceutical markets, as well unfavourable revisions to our currency assumptions, affecting our assessment of market growth when measured in US dollars. Slovenia's Risk/Reward Rating (RRR) score remains weak - a combination of economic READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • GlaxoSmithKline (GSK)
  • Krka
  • Lek (Novartis/Sandoz)
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

1. SWOT

2. Political

3. Economic

4. Business Environment

5. Industry Forecast

6. Pharmaceutical Market Forecast

7. Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovenia 2010-2018)

8. Healthcare Market Forecast

- Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2010-2018)
- Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2010-2018)
- Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2010-2018)

9. Prescription Drug Market Forecast

- Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovenia 2010-2018)

10. Patented Drug Market Forecast

- Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovenia 2010-2018)

11. Generic Drug Market Forecast

- Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovenia 2010-2018)

12. OTC Medicine Market Forecast

- Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovenia 2010-2018)

13. Pharmaceutical Trade Forecast

- Table: Pharmaceutical Trade Data And Forecasts (Slovenia 2012-2018)
- Table: Pharmaceutical Trade Data And Forecasts local currency (Slovenia 2012-2018)

14. Key Risks To The Forecast Scenario

15. Macroeconomic Forecasts

16. Economic Analysis

17. Real GDP By Expenditure Breakdown

18. Risks To Outlook

- Table: Economic Activity (Slovenia 2009-2018)

19. Industry Risk Reward Ratings

20. Central And Eastern Europe Risk/Reward Ratings

21. Slovenia Risk/Reward Ratings

22. Rewards

23. Risks

24. Market Overview

25. Industry Trends And Developments

26. Epidemiology

27. Healthcare Sector

28. Research & Development

29. Regulatory Development

30. Intellectual Property Regime

31. Pricing Regime

32. Reimbursement Regime

33. Competitive Landscape

34. Pharmaceutical Industry

35. Recent Pharmaceutical Industry Developments

36. Company Profile

- Krka
- Lek (Novartis/Sandoz)
- GlaxoSmithKline (GSK)
- Sanofi
- Pfizer
- Novartis
- Merck & Co

37. Demographic Forecast

- Table: Slovenia's Population By Age Group, 1990-2020, 1990-2020 ('000)
- Table: Slovenia's Population By Age Group, 1990-2020 (% of total)
- Table: Slovenia's Key Population Ratios, 1990-2020
- Table: Slovenia's Rural And Urban Population, 1990-2020

38. Glossary

39. Methodology

40. Pharmaceutical Expenditure Forecast Model

41. Healthcare Expenditure Forecast Model

42. Notes On Methodology

43. Risk/Reward Index Methodology

44. Index Overview

- Table: Pharmaceutical Risk/Reward Index Indicators

45. Indicator Weightings

Note: Product cover images may vary from those shown

- GlaxoSmithKline (GSK)
- Krka
- Lek (Novartis/Sandoz)
- Merck & Co
- Novartis
- Pfizer
- Sanofi

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • AbbVie Ltd.
  • Sigma-Aldrich Corporation
  • Bruker Corporation
  • Raumedic AG
  • Ferring Pharmaceuticals B.V.
  • Baxter International Inc.